CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,696,438 | -15.8% | 59,406 | +4.2% | 0.52% | -12.9% |
| Q2 2023 | $3,202,113 | +33.8% | 57,038 | +7.8% | 0.60% | +25.4% |
| Q1 2023 | $2,392,531 | +64.2% | 52,897 | +47.6% | 0.48% | +51.1% |
| Q4 2022 | $1,457,262 | +380.9% | 35,849 | +672.8% | 0.32% | +356.5% |
| Q3 2022 | $303,000 | +11.0% | 4,639 | +3.3% | 0.07% | +16.9% |
| Q2 2022 | $273,000 | +17.7% | 4,489 | +21.4% | 0.06% | +37.2% |
| Q1 2022 | $232,000 | +1.3% | 3,699 | +80.5% | 0.04% | 0.0% |
| Q3 2021 | $229,000 | -31.0% | 2,049 | 0.0% | 0.04% | -31.7% |
| Q2 2021 | $332,000 | +24.3% | 2,049 | -6.7% | 0.06% | +12.5% |
| Q1 2021 | $267,000 | +0.8% | 2,195 | +26.8% | 0.06% | -15.2% |
| Q4 2020 | $265,000 | +13.7% | 1,731 | -37.8% | 0.07% | -4.3% |
| Q3 2020 | $233,000 | -2.5% | 2,781 | -14.5% | 0.07% | -16.9% |
| Q2 2020 | $239,000 | – | 3,251 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |